Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study.
Fiche publication
Date publication
août 2021
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
Tous les auteurs :
Davie A, Cuyun Carter G, Rider A, Bailey A, Lewis K, Price G, Ostojic H, Ringeisen F, Pivot X
Lien Pubmed
Résumé
Patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) and disease-related poor prognostic factors are not well characterized. We aimed to describe patient demographics, disease characteristics, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- ABC patients with these factors [at the time when cyclin-dependent kinase (CDK) 4 and 6 inhibitors were being introduced] and understand how these factors informed treatment decisions at the time of the survey.
Mots clés
HR+/HER2−, advanced breast cancer, health-related quality of life, outcomes, prognostic factors, real-world, treatment patterns
Référence
ESMO Open. 2021 Aug 6;6(4):100226